“We do not know yet the magnitude of the problem, but given the number of individuals of all ages who have been or will be infected with SARS-CoV-2, the coronavirus that causes COVID-19, the public health impact could be profound,” said Francis Collins, MD, PhD, director of the NIH.
The initial questions the research will consider are:
- What does the spectrum of recovery from SARS-CoV-2 infection look like across the population?
- How many people continue to have symptoms of COVID-19, or even develop new symptoms, after infection?
- What is the underlying biological cause of these prolonged symptoms?
- What makes some people vulnerable to this but not others?
- Does SARS-CoV-2 infection trigger changes in the body that increase the risk of other conditions, such as chronic heart or brain disorders?
More articles on public health:
Severely sick newborn with new COVID-19 variant had 51,418X higher viral load
Patients’ value of vaccine efficacy outweighs side effect concerns, Stanford study shows
J&J’s vaccine is safe, FDA says; California variant more contagious, early research shows — 7 COVID-19 updates
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
